The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Radiotherapy in SCLC: where do we stand and what is the future?
Bjorn Henning Gronberg, MD, PhD, Norwegian University of Science and Technology, Trondheim, Norway, discusses the role of radiotherapy in small cell lung cancer (SCLC), highlighting the need to optimize treatment for limited-stage disease, and notes that prophylactic cranial irradiation’s effectiveness is still uncertain, while thoracic radiotherapy in extensive disease may not be beneficial. Dr Gronberg also mentions the potential of stereotactic radiosurgery for brain metastases, suggesting a shift in treatment approach for selected patients with oligometastases. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
